VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
-2.98%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$251M
AUM Growth
-$19M
(-7%)
Cap. Flow
-$3.64M
Cap. Flow
% of AUM
-1.45%
Top 10 Holdings %
Top 10 Hldgs %
7.1%
Holding
477
New
43
Increased
256
Reduced
137
Closed
41
Top Buys
| 1 |
The Mosaic Company
MOS
|
$900K |
| 2 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$877K |
| 3 |
Enphase Energy
ENPH
|
$858K |
| 4 |
Gartner
IT
|
$732K |
| 5 |
Devon Energy
DVN
|
$727K |
Top Sells
| 1 |
L3Harris
LHX
|
$740K |
| 2 |
Cheniere Energy
CQP
|
$732K |
| 3 |
Agilent Technologies
A
|
$713K |
| 4 |
Copart
CPRT
|
$688K |
| 5 |
Equifax
EFX
|
$678K |
Sector Composition
| 1 | Healthcare | 18.83% |
| 2 | Real Estate | 17.55% |
| 3 | Materials | 12.77% |
| 4 | Financials | 9.88% |
| 5 | Energy | 9.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
PMV Pharmaceuticals
PMVP
$80.5M
| $132K | 0.05% |
11,061
+75
| +0.7% | +$895 |
|
377
Design Therapeutics
DSGN
$334M
| $130K | 0.05% |
7,775
+59
| +0.8% | +$986 |
|
378
Iovance Biotherapeutics
IOVA
$785M
| $130K | 0.05% |
13,519
+104
| +0.8% | +$1K |
|
379
Arvinas
ARVN
$572M
| $129K | 0.05% |
2,900
+20
| +0.7% | +$890 |
|
380
Cytokinetics
CYTK
$6.15B
| $129K | 0.05% |
2,665
+18
| +0.7% | +$871 |
|
381
AnaptysBio
ANAB
$627M
| $128K | 0.05% |
5,027
+42
| +0.8% | +$1.07K |
|
382
Editas Medicine
EDIT
$224M
| $128K | 0.05% |
10,440
+70
| +0.7% | +$858 |
|
383
Stoke Therapeutics
STOK
$1.08B
| $128K | 0.05% |
9,970
+75
| +0.8% | +$963 |
|
|
KDNY
384
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $128K | 0.05% |
6,490
+49
| +0.8% | +$966 |
|
385
Fate Therapeutics
FATE
$116M
| $126K | 0.05% |
5,607
+41
| +0.7% | +$921 |
|
386
Inovio Pharmaceuticals
INO
$143M
| $125K | 0.05% |
6,045
+44
| +0.7% | +$910 |
|
|
TVRD
387
Tvardi Therapeutics, Inc. Common Stock
TVRD
$270M
| $125K | 0.05% |
372
+3
| +0.8% | +$1.01K |
|
388
Allogene Therapeutics
ALLO
$249M
| $124K | 0.05% |
11,462
+79
| +0.7% | +$855 |
|
389
Arrowhead Research
ARWR
$4.01B
| $124K | 0.05% |
3,742
+24
| +0.6% | +$795 |
|
390
Invivyd
IVVD
$214M
| $124K | 0.05% |
39,564
+283
| +0.7% | +$887 |
|
391
Replimune Group
REPL
$457M
| $124K | 0.05% |
7,153
+45
| +0.6% | +$780 |
|
392
Alector
ALEC
$286M
| $123K | 0.05% |
12,995
+97
| +0.8% | +$918 |
|
393
Revolution Medicines
RVMD
$7.32B
| $123K | 0.05% |
6,214
+45
| +0.7% | +$891 |
|
|
IMGO
394
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $123K | 0.05% |
8,189
+55
| +0.7% | +$826 |
|
395
Crinetics Pharmaceuticals
CRNX
$3.27B
| $122K | 0.05% |
6,228
+48
| +0.8% | +$940 |
|
396
MeiraGTx Holdings
MGTX
$581M
| $121K | 0.05% |
14,362
+98
| +0.7% | +$826 |
|
|
CERE
397
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $121K | 0.05% |
4,295
+36
| +0.8% | +$1.01K |
|
398
Arcturus Therapeutics
ARCT
$461M
| $120K | 0.05% |
8,092
+53
| +0.7% | +$786 |
|
399
Protagonist Therapeutics
PTGX
$3.63B
| $120K | 0.05% |
14,237
+108
| +0.8% | +$910 |
|
|
CMPS
400
Compass Pathways
CMPS
$468M
| $119K | 0.05% |
11,061
+75
| +0.7% | +$807 |
|